Edition:
India

Eagle Pharmaceuticals Inc (EGRX.OQ)

EGRX.OQ on NASDAQ Stock Exchange Global Market

52.61USD
25 Jun 2019
Change (% chg)

-- (--)
Prev Close
$52.61
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
77,322
52-wk High
$85.66
52-wk Low
$36.10

Latest Key Developments (Source: Significant Developments)

Eagle Pharmaceuticals Inc - On Feb 20, U.S. FDA, Issued Decision In Favor Of Co, Regarding Scope Of Exclusivity For Bendeka - SEC Filing
Thursday, 21 Feb 2019 

Feb 21 (Reuters) - Eagle Pharmaceuticals Inc ::EAGLE PHARMACEUTICALS INC - ON FEB 20, U.S. FDA, ISSUED DECISION IN FAVOR OF CO, REGARDING SCOPE OF EXCLUSIVITY FOR BENDEKA™ - SEC FILING.EAGLE PHARMACEUTICALS - PURSUANT TO FDA DECISION, NO BENDAMUSTINE PRODUCT MAY LAUNCH IN U.S. UNTIL DEC. 7, 2022 UNLESS CLINICALLY SUPERIOR TO BENDEKA.  Full Article

Eagle Pharmaceuticals Announces Positive Results Of Pre-Clinical Study Conducted To Evaluate Effects Of Ryanodex In Acute Radiation Syndrome (ARS)
Tuesday, 27 Nov 2018 

Nov 27 (Reuters) - Eagle Pharmaceuticals Inc ::EAGLE PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS OF PRE-CLINICAL STUDY CONDUCTED TO EVALUATE EFFECTS OF RYANODEX IN ACUTE RADIATION SYNDROME (ARS).EAGLE PHARMACEUTICALS INC - TO EXPLORE ARS INDICATION TO TREAT INDIVIDUALS EXPOSED TO HIGH DOSES OF RADIATION.EAGLE PHARMACEUTICALS INC - PLANS TO CONDUCT FURTHER RESEARCH FOR TREATMENT OF POST-IRRADIATION HEMATOPOIETIC SYNDROME.EAGLE PHARMACEUTICALS INC - RYANODEX TREATMENT GROUP HAD OVERALL LESS MORTALITY POST-TREATMENT THAN NON-TREATED ANIMALS WITH ARS.EAGLE PHARMACEUTICALS - ADDITIONAL RESEARCH ONGOING TO EVALUATE HEMATOPOIETIC SYNDROME IN CERTAIN CANCER PATIENTS UNDERGOING RADIATION THERAPY.  Full Article

Eagle Pharmaceuticals Inc Reports Third Quarter 2018 Results
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Eagle Pharmaceuticals Inc ::EAGLE PHARMACEUTICALS, INC. REPORTS THIRD QUARTER 2018 RESULTS.Q3 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.18.Q3 EARNINGS PER SHARE $0.91.Q3 REVENUE $51.3 MILLION VERSUS I/B/E/S VIEW $53.4 MILLION.Q3 EARNINGS PER SHARE VIEW $0.98 -- THOMSON REUTERS I/B/E/S.REITERATING 2018 RESEARCH AND DEVELOPMENT EXPENSE & SG&A EXPENSE GUIDANCE.  Full Article

Eagle Pharmaceuticals Commences $50 Mln Accelerated Share Repurchase
Tuesday, 30 Oct 2018 

Oct 30 (Reuters) - Eagle Pharmaceuticals Inc ::EAGLE PHARMACEUTICALS COMMENCES $50 MILLION ACCELERATED SHARE REPURCHASE AS PART OF NEW $150 MILLION SHARE REPURCHASE AUTHORIZATION.Q3 2018 PRELIMINARY EPS IS EXPECTED TO BE $0.94 PER BASIC AND $0.91 PER DILUTED SHARE.Q3 2018 PRELIMINARY ADJUSTED NON-GAAP EPS IS EXPECTED TO BE $1.22 PER BASIC AND $1.18 PER DILUTED SHARE.COMPANY INTENDS TO USE CASH ON HAND TO FUND ASR PROGRAM.Q3 2018 PRELIMINARY REVENUE IS EXPECTED TO BE $51 MILLION.Q3 EARNINGS PER SHARE VIEW $0.98, REVENUE VIEW $55.2 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Eagle Pharmaceuticals Reports Q4 EPS Of $0.58
Monday, 26 Feb 2018 

Feb 26 (Reuters) - Eagle Pharmaceuticals Inc ::EAGLE PHARMACEUTICALS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS.Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.00.Q4 EARNINGS PER SHARE $0.58.Q4 REVENUE $46.8 MILLION VERSUS $81.1 MILLION.Q4 EARNINGS PER SHARE VIEW $1.00, REVENUE VIEW $52.9 MILLION -- THOMSON REUTERS I/B/E/S.2018 RESEARCH AND DEVELOPMENT EXPENSE IS EXPECTED TO BE IN RANGE OF $46 MILLION TO $50 MILLION.  Full Article

Iridian Asset Management Reports 10.1 Pct Passive Stake In Eagle Pharmaceuticals
Tuesday, 9 Jan 2018 

Jan 8 (Reuters) - Iridian Asset Management::IRIDIAN ASSET MANAGEMENT REPORTS 10.1 PERCENT PASSIVE STAKE IN EAGLE PHARMACEUTICALS AS OF DEC 31, 2017 - SEC FILING‍​.  Full Article

Eagle Pharmaceuticals Commences Pivotal Study For Fulvestrant
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Eagle Pharmaceuticals Inc ::EAGLE PHARMACEUTICALS COMMENCES PIVOTAL STUDY FOR FULVESTRANT.EAGLE PHARMACEUTICALS- ANTICIPATES COMPLETION OF FULVESTRANT STUDY WITHIN TWELVE MONTHS, AND AN EXPECTED NDA FILING IN Q4 OF 2018.  Full Article

Eagle Pharmaceuticals Q3 earnings per share $0.98
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Eagle Pharmaceuticals Inc :Eagle Pharmaceuticals Inc reports third quarter 2017 results.Q3 adjusted non-GAAP earnings per share $1.22.Q3 earnings per share $0.98.Q3 revenue $63 million versus I/B/E/S view $51.9 million.Q3 earnings per share view $0.80 -- Thomson Reuters I/B/E/S.Expect full year 2017 research and development expense will be consistent with upper end of $31-$35 million range​.Plan to begin dosing patients in Fulvestrant study in a few weeks and expect to file an NDA in Q4 of 2018​.Expect full year 2017 SG&A expense to be in range of $67 million - $70 million, slightly higher than previous guidance​.Will continue purchasing up to an additional $100 million shares under current share repurchase plan​.On PEMFEXY, says "hope to find a way to market" as soon as possible, once co's litigation with Eli Lilly is resolved​.  Full Article

EAGLE PHARMACEUTICALS RECEIVES TENTATIVE FDA APPROVAL FOR PEMFEXY
Saturday, 28 Oct 2017 

Oct 27 (Reuters) - Eagle Pharmaceuticals Inc ::EAGLE PHARMACEUTICALS RECEIVES TENTATIVE FDA APPROVAL FOR PEMFEXY (PEMETREXED INJECTION) READY-TO-DILUTE.EAGLE PHARMACEUTICALS INC - ‍FDA HAS GRANTED TENTATIVE APPROVAL FOR COMPANY'S PEMFEXY​.  Full Article

Eagle Pharmaceuticals licenses Japanese rights for Bendamustine HCl
Wednesday, 20 Sep 2017 

Sept 20 (Reuters) - Eagle Pharmaceuticals Inc :Eagle Pharmaceuticals licenses Japanese rights for Bendamustine Hydrochloride ready-to-dilute and rapid infusion injection products to Symbio Pharmaceuticals Limited.$12.5 million upfront payment plus future potential milestones and royalty payments are part of deal​.Symbio has estimated that sales of Treakisym are estimated to grow to $90 million in 2018​.Company will also receive royalties on future net sales of licensed Bendamustine products.Symbio will target for approval of a product in 2020​.  Full Article